Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Ribeiro, A. Sebastião, A. Mendonça (2002)
Adenosine receptors in the nervous system: pathophysiological implicationsProgress in Neurobiology, 68
An-Hu Li, Stefano Moro, Nancy Forsyth, N. Melman, X. Ji, Kenneth Jacobson (1999)
Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, 42 4
R. Volpini, S. Costanzi, S. Vittori, G. Cristalli, K. Klotz (2003)
Medicinal chemistry and pharmacology of A2B adenosine receptors.Current topics in medicinal chemistry, 3 4
B. Fredholm (2003)
Adenosine receptors as targets for drug development.Drug news & perspectives, 16 5
B. Fredholm, G. Arslan, L. Halldner, B. Kull, G. Schulte, W. Wasserman (2000)
Structure and function of adenosine receptors and their genesNaunyn-Schmiedeberg's Archives of Pharmacology, 362
Anna Robeva, R. Woodard, Xiaowei Jin, Zhenhai Gao, S. Bhattacharya, H. Taylor, D. Rosin, J. Linden (1996)
Molecular characterization of recombinant human adenosine receptorsDrug Development Research, 39
S. Costanzi, C. Lambertucci, S. Vittori, R. Volpini, G. Cristalli (2003)
2- and 8-alkynyladenosines: conformational studies and docking to human adenosine A3 receptor can explain their different biological behavior.Journal of molecular graphics & modelling, 21 4
T. Mirzadegan, G. Benkö, S. Filipek, K. Palczewski (2003)
Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin.Biochemistry, 42 10
H. Barbhaiya, R. McClain, A. IJzerman, S. Rivkees (1996)
Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding.Molecular pharmacology, 50 6
J. Shimada, F. Suzuki, H. Nonaka, A. Ishii, S. Ichikawa (1992)
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.Journal of medicinal chemistry, 35 12
C. Müller (2003)
Medicinal chemistry of adenosine A3 receptor ligands.Current topics in medicinal chemistry, 3 4
S. Todde, R. Moresco, P. Simonelli, P. Baraldi, B. Cacciari, G. Spalluto, K. Varani, A. Monopoli, M. Matarrese, A. Carpinelli, F. Magni, M. Kienle, F. Fazio (2000)
Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography.Journal of medicinal chemistry, 43 23
W. Soudijn, I. Wijngaarden, A. IJzerman (2003)
Medicinal chemistry of adenosine A1 receptor ligands.Current topics in medicinal chemistry, 3 4
(2000)
Triazolopurines, process for their preparation and their use as medicaments
A. Townsend-Nicholson, P. Schofield (1994)
A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding.The Journal of biological chemistry, 269 4
T. Klabunde, G. Hessler (2002)
Drug Design Strategies for Targeting G‐Protein‐Coupled ReceptorsChemBioChem, 3
I. Feoktistov, I. Biaggioni, R. Polosa, S. Holgate (1998)
Adenosine A2B receptors: a novel therapeutic target in asthma?Trends in pharmacological sciences, 19 4
S. Moro, G. Spalluto, K. Jacobson (2005)
Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example.Trends in pharmacological sciences, 26 1
M. Stewart, A. Steinig, Chienling Ma, Jianping Song, B. McKibben, A. Castelhano, S. Maclennan (2004)
[3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors.Biochemical pharmacology, 68 2
R. Brambilla, F. Cattabeni, S. Ceruti, D. Barbieri, C. Franceschi, Y.-C. Kim, K. Jacobson, K. Klotz, M. Lohse, M. Abbracchio (2000)
Activation of the A3 adenosine receptor affects cell cycle progression and cell growthNaunyn-Schmiedeberg's Archives of Pharmacology, 361
P. Ferrarini, C. Mori, C. Manera, A. Martinelli, F. Mori, G. Saccomanni, P. Barili, L. Betti, G. Giannaccini, L. Trincavelli, A. Lucacchini (2000)
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.Journal of medicinal chemistry, 43 15
J. Auchampach, Xiaowei Jin, Tina Wan, G. Caughey, Joel Linden (1997)
Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor.Molecular pharmacology, 52 5
P. Baraldi, M. Tabrizi, D. Preti, A. Bovero, R. Romagnoli, F. Fruttarolo, Naser Zaid, A. Moorman, K. Varani, S. Gessi, S. Merighi, P. Borea (2004)
Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.Journal of medicinal chemistry, 47 6
Anna Maconi, G. Pastorin, T. Ros, G. Spalluto, Zhang-Guo Gao, K. Jacobson, P. Baraldi, B. Cacciari, K. Varani, S. Moro, P. Borea (2002)
Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist.Journal of medicinal chemistry, 45 17
E. Jackson, W. Herzer, F. Suzuki (1993)
KF17837 is an A2 adenosine receptor antagonist in vivo.The Journal of pharmacology and experimental therapeutics, 267 3
K. Pierce, T. Furlong, L. Selbie, J. Shine (1992)
Molecular cloning and expression of an adenosine A2b receptor from human brain.Biochemical and biophysical research communications, 187 1
P. Baraldi, B. Cacciari, G. Spalluto, M. Villatoro, C. Zocchi, S. Dionisotti, E. Ongini (1996)
Pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine Derivatives: Potent and Selective A2A Adenosine Antagonists.ChemInform, 27
V. Ozola, Mark Thorand, M. Diekmann, Ramatullah Qurishi, B. Schumacher, K. Jacobson, C. Müller (2003)
2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors.Bioorganic & medicinal chemistry, 11 3
Y. Kim, X. Ji, N. Melman, J. Linden, K. Jacobson (2000)
Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors.Journal of medicinal chemistry, 43 6
Soon-Ai Kim, Melissa Marshall, N. Melman, H. Kim, C. Müller, J. Linden, K. Jacobson (2002)
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.Journal of medicinal chemistry, 45 11
(1999)
Drug Des Discov
G. Cristalli, C. Lambertucci, S. Taffi, S. Vittori, R. Volpini (2003)
Medicinal chemistry of adenosine A2A receptor agonists.Current topics in medicinal chemistry, 3 4
M. Lohse, K. Klotz, J. Lindenborn-Fotinos, M. Reddington, U. Schwabe, R. Olsson (1987)
8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) — a selective high affinity antagonist radioligand for A1 adenosine receptorsNaunyn-Schmiedeberg's Archives of Pharmacology, 336
A. Dhalla, J. Shryock, R. Shreeniwas, L. Belardinelli (2003)
Pharmacology and therapeutic applications of A1 adenosine receptor ligands.Current topics in medicinal chemistry, 3 4
K. Klotz (2000)
Adenosine receptors and their ligandsNaunyn-Schmiedeberg's Archives of Pharmacology, 362
T. Palmer, K. Jacobson, G. Stiles (1992)
Immunological identification of A2 adenosine receptors by two antipeptide antibody preparations.Molecular pharmacology, 42 3
J. Muijlwijk-Koezen, Henk Timmerman, R. Vollinga, J. Künzel, M. Groote, Sven Visser, A. Ijzerman (2001)
Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists.Journal of medicinal chemistry, 44 5
Zhang-Guo Gao, Aishe Chen, D. Barak, Soo-Kyung Kim, C. Müller, K. Jacobson (2002)
Identification by Site-directed Mutagenesis of Residues Involved in Ligand Recognition and Activation of the Human A3 Adenosine Receptor*The Journal of Biological Chemistry, 277
T. Okamura, Y. Kurogi, H. Nishikawa, K. Hashimoto, H. Fujiwara, Y. Nagao (2002)
1,2,4-Triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A(3) receptor ligands.Journal of medicinal chemistry, 45 17
C. Müller, J. Sandoval-Ramírez, U. Schobert, U. Geis, W. Frobenius, K. Klotz (1998)
8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists.Bioorganic & medicinal chemistry, 6 6
K. Jung, Soo-Kyung Kim, Zhang-Guo Gao, A. Gross, N. Melman, K. Jacobson, Yong‐Chul Kim (2004)
Structure-activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists.Bioorganic & medicinal chemistry, 12 3
A. Carotti, A. Stefanachi, E. Raviña, E. Sotelo, M. Loza, M. Cadavid, N. Centeno, O. Nicolotti (2004)
8-Substituted-9-deazaxanthines as adenosine receptor ligands: design, synthesis and structure-affinity relationships at A2B.European journal of medicinal chemistry, 39 10
Yong‐Chul Kim, Y. Karton, X. Ji, N. Melman, J. Linden, K. Jacobson (1999)
Acyl-Hydrazide Derivatives of a Xanthine Carboxylic Congener (XCC) as Selective Antagonists at Human A2B Adenosine ReceptorsDrug development research, 47
P. Galen, P. Nissen, I. Wijngaarden, A. IJzerman, W. Soudijn (1991)
1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists.Journal of medicinal chemistry, 34 3
A. Tucker, A. Robeva, H. Taylor, D. Holeton, M. Bockner, K. Lynch, J. Linden (1994)
A1 adenosine receptors. Two amino acids are responsible for species differences in ligand recognition.The Journal of biological chemistry, 269 45
R. Stenkamp, D. Teller, K. Palczewski (2002)
Crystal Structure of Rhodopsin: A G‐Protein‐Coupled ReceptorChemBioChem, 3
J. Matasi, John Caldwell, Jinsong Hao, B. Neustadt, L. Arik, C. Foster, J. Lachowicz, D. Tulshian (2005)
The discovery and synthesis of novel adenosine receptor (A(2A)) antagonists.Bioorganic & medicinal chemistry letters, 15 5
V. Colotta, D. Catarzi, F. Varano, L. Cecchi, G. Filacchioni, C. Martini, L. Trincavelli, A. Lucacchini (2000)
1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists.Journal of medicinal chemistry, 43 6
Y. Nonaka, J. Shimada, H. Nonaka, N. Koike, N. Aoki, Hiroyuki Kobayashi, H. Kase, Kazuo Yamaguchi, F. Suzuki (1993)
Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine.Journal of medicinal chemistry, 36 23
J. Pfister, L. Belardinelli, G. Lee, R. Lum, P. Milner, W. Stanley, J. Linden, S. Baker, G. Schreiner (1997)
Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.Journal of medicinal chemistry, 40 12
C. Vu, P. Shields, B. Peng, G. Kumaravel, Xiaowei Jin, D. Phadke, Joy Wang, T. Engber, Eman Ayyub, R. Petter (2004)
Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.Bioorganic & medicinal chemistry letters, 14 19
K. Jacobson, Kyung-Sun Park, Ji-long Jiang, Yong‐Chul Kim, M. Olah, G. Stiles, X. Ji (1997)
Pharmacological characterization of novel A3 adenosine receptor-selective antagonistsNeuropharmacology, 36
E. Tilburg, P. Klein, M. Groote, M. Beukers, A. IJzerman (2001)
Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor.Bioorganic & medicinal chemistry letters, 11 15
J. Hockemeyer, J. Burbiel, C. Müller (2004)
Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease.The Journal of organic chemistry, 69 10
J. Kim, Q. Jiang, M. Glashofer, S. Yehle, J. Wess, K. Jacobson (1996)
Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition.Molecular pharmacology, 49 4
R. Lefkowitz (2004)
Historical review: a brief history and personal retrospective of seven-transmembrane receptors.Trends in pharmacological sciences, 25 8
D. Catarzi, V. Colotta, F. Varano, F. Calabri, Ombretta Lenzi, G. Filacchioni, L. Trincavelli, C. Martini, Andrea Tralli, C. Montopoli, S. Moro (2005)
2-aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists.Bioorganic & medicinal chemistry, 13 3
S. Moro, K. Jacobson (2002)
Molecular modeling as a tool to investigate molecular recognition in P2Y receptors.Current pharmaceutical design, 8 26
P. Baraldi, B. Cacciari, G. Spalluto, M. Villatoro, C. Zocchi, S. Dionisotti, E. Ongini (1996)
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.Journal of medicinal chemistry, 39 5
T. Okamura, Y. Kurogi, K. Hashimoto, Seiji Sato, H. Nishikawa, K. Kiryu, Y. Nagao (2004)
Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma.Bioorganic & medicinal chemistry letters, 14 14
T. Furlong, K. Pierce, L. Selbie, J. Shine (1992)
Molecular characterization of a human brain adenosine A2 receptor.Brain research. Molecular brain research, 15 1-2
Kirsten Scholz‐Pedretti, J. Pfeilschifter, M. Kaszkin (2001)
Potentiation of cytokine induction of group IIA phospholipase A2 in rat mesangial cells by ATP and adenosine via the A2A adenosine receptorBritish Journal of Pharmacology, 132
Y. Kim, X. Ji, K. Jacobson (1996)
Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype.Journal of medicinal chemistry, 39 21
B. Fredholm (1996)
Chapter 11 Adenosine and NeuroprotectionInternational Review of Neurobiology, 40
M. Shamim, Dieter Ukena, W. Padgett, John Daly (1989)
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, 32 6
R. Sauer, Juris Maurinsh, Ulrike Reith, Friederike Fülle, K. Klotz, Christa Müller (2000)
Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists.Journal of medicinal chemistry, 43 3
Xiao-duoseqkat Ji, Y. Kim, D. Ahern, J. Linden, K. Jacobson (2001)
[3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors.Biochemical pharmacology, 61 6
(2000)
A bromine atom in C8 position of 9-substituted adenines enhances A 2A affinity
M. Zwart, R. Vollinga, M. Beukers, Danielle Sleegers, J. Künzel, M. Groote, A. IJzerman (1999)
Potent antagonists for the human adenosine A2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinityDrug Development Research, 48
B. Fredholm (1997)
Adenosine and neuroprotection.International review of neurobiology, 40
Luo Yan, C. Müller (2004)
Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability.Journal of medicinal chemistry, 47 4
T. Webb, D. Lvovskiy, Soon-Ai Kim, X. Ji, N. Melman, J. Linden, K. Jacobson (2003)
Quinazolines as adenosine receptor antagonists: SAR and selectivity for A2B receptors.Bioorganic & medicinal chemistry, 11 1
Zhang-Guo Gao, Soo-Kyung Kim, Thibaud Biadatti, Wangzhong Chen, Kyeong Lee, D. Barak, S. Kim, Carl Johnson, K. Jacobson (2002)
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.Journal of medicinal chemistry, 45 20
P. Baraldi, B. Cacciari, S. Moro, G. Spalluto, G. Pastorin, T. Ros, K. Klotz, K. Varani, S. Gessi, P. Borea (2002)
Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists.Journal of medicinal chemistry, 45 4
F. Settimo, G. Primofiore, S. Taliani, A. Marini, C. Motta, E. Novellino, G. Greco, A. Lavecchia, L. Trincavelli, C. Martini (2001)
3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists.Journal of medicinal chemistry, 44 3
T. Okamura, Y. Kurogi, K. Hashimoto, H. Nishikawa, Y. Nagao (2004)
Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands.Bioorganic & medicinal chemistry letters, 14 10
M. Olah, H. Ren, J. Ostrowski, K. Jacobson, G. Stiles (1992)
Cloning, expression, and characterization of the unique bovine A1 adenosine receptor. Studies on the ligand binding site by site-directed mutagenesis.The Journal of biological chemistry, 267 15
C. Vu, D. Pan, B. Peng, Li Sha, G. Kumaravel, Xiaowei Jin, D. Phadke, T. Engber, Carol Huang, Jennifer Reilly, S. Tam, R. Petter (2004)
Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles.Bioorganic & medicinal chemistry letters, 14 19
Kenneth Jacobson, Carsten Hoffmann, F. Cattabeni, M. Abbracchio (1999)
Adenosine-induced cell death: evidence for receptor-mediated signallingApoptosis, 4
S. Rosi, K. McGann, B. Hauss-Wegrzyniak, G. Wenk (2003)
The influence of brain inflammation upon neuronal adenosine A2B receptorsJournal of Neurochemistry, 86
Joel Linden, H. Taylor, Anna Robeva, Amy Tucker, Jörg Stehle, S. Rivkees, J. Fink, S. Reppert (1993)
Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution.Molecular pharmacology, 44 3
Stefano Moro, A. Rhee, L. Sanders, Kenneth Jacobson (1998)
Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model.Journal of medicinal chemistry, 41 1
K. Jacobson, S. Tchilibon, B. Joshi, Zhang-Guo Gao (2003)
Chapter 13. A3 Adenosine Receptors.Annual reports in medicinal chemistry, 38
J. Muijlwijk-Koezen, H. Timmerman, H. Goot, W. Menge, J. Künzel, M. Groote, A. IJzerman (2000)
Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor.Journal of medicinal chemistry, 43 11
P. Pauwels, T. Wurch (2007)
Review: Amino acid domains involved in constitutive activation of G-protein-coupled receptorsMolecular Neurobiology, 17
Ronald Erickson, R. Hiner, Scott Feeney, Paul Blake, W. Rzeszotarski, Rickey Hicks, Diane Costello, Mary Abreu (1991)
1,3,8-trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A1/A2 affinity.Journal of medicinal chemistry, 34 4
Hairuo Peng, G. Kumaravel, Gang Yao, Li Sha, Joy Wang, H. Vlijmen, T. Bohnert, Carol Huang, C. Vu, C. Ensinger, Hexi Chang, T. Engber, E. Whalley, R. Petter (2004)
Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.Journal of medicinal chemistry, 47 25
S. Poucher, J. Keddie, P. Singh, S. Stoggall, P. Caulkett, G. Jones, M. Collis (1995)
The in vitro pharmacology of ZM 241385, a potent, non‐xanthine, A2a selective adenosine receptor antagonistBritish Journal of Pharmacology, 115
K. Jacobson, D. Ukena, W. Padgett, K. Kirk, J. Daly (1987)
Molecular probes for extracellular adenosine receptors.Biochemical pharmacology, 36 10
I. Feoktistov, I. Biaggioni (1995)
Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma.The Journal of clinical investigation, 96 4
C. Salvatore, M. Jacobson, H. Taylor, J. Linden, Robert Johnson (1993)
Molecular Cloning and Characterization of the Human A_3 Adenosine ReceptorProceedings of the National Academy of Sciences of the United States of America
G. Pastorin, T. Ros, G. Spalluto, F. Deflorian, S. Moro, B. Cacciari, P. Baraldi, S. Gessi, K. Varani, P. Borea (2003)
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.Journal of medicinal chemistry, 46 20
F. Libert, J. Sande, A. Lefort, Armin Czernilofsky, J. Dumont, Gilbert Vassart, Helmut Ensinger, Klaus Mendla (1992)
Cloning and functional characterization of a human A1 adenosine receptor.Biochemical and biophysical research communications, 187 2
L. Knutsen, S. Weiss (2001)
KW-6002 (Kyowa Hakko Kogyo).Current opinion in investigational drugs, 2 5
P. Ferrarini, L. Betti, T. Cavallini, G. Giannaccini, A. Lucacchini, C. Manera, A. Martinelli, G. Ortore, G. Saccomanni, T. Tuccinardi (2004)
Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives.Journal of medicinal chemistry, 47 12
(2003)
The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.Molecular pharmacology, 63 6
(2002)
J Med Chem
C. Műller, B. Stein (1996)
Adenosine Receptor Antagonists: Structures and Potential Therapeutic ApplicationsCurrent Pharmaceutical Design
K. Jacobson, D. Lubitz, J. Daly, B. Fredholm (1996)
Adenosine receptor ligands: differences with acute versus chronic treatment.Trends in pharmacological sciences, 17 3
C. Vu, D. Pan, B. Peng, G. Kumaravel, G. Smits, Xiaowei Jin, D. Phadke, T. Engber, Carol Huang, Jennifer Reilly, S. Tam, Donna Grant, G. Hetu, R. Petter (2004)
Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.Journal of medicinal chemistry, 48 6
P. Fishman, S. Bar‐Yehuda (2003)
Pharmacology and therapeutic applications of A3 receptor subtype.Current topics in medicinal chemistry, 3 4
J. Muijlwijk-Koezen, Henk Timmerman, R. Link, H. Goot, A. Ijzerman (1998)
A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds.Journal of medicinal chemistry, 41 21
P. Baraldi, B. Cacciari, G. Spalluto, M. Bergonzoni, S. Dionisotti, E. Ongini, K. Varani, P. Borea (1998)
Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.Journal of medicinal chemistry, 41 12
P. Baraldi, B. Cacciari, R. Romagnoli, S. Merighi, K. Varani, P. Borea, G. Spalluto (2000)
A3 Adenosine Receptor Ligands: History and PerspectivesMedicinal Research Reviews, 20
O. Becker, Y. Marantz, S. Shacham, B. Inbal, Alexander Heifetz, O. Kalid, S. Bar-Haim, D. Warshaviak, M. Fichman, S. Noiman (2004)
G protein-coupled receptors: in silico drug discovery in 3D.Proceedings of the National Academy of Sciences of the United States of America, 101 31
Pingbo Huang, E. Lazarowski, R. Tarran, S. Milgram, R. Boucher, M. Stutts (2001)
Compartmentalized autocrine signaling to cystic fibrosis transmembrane conductance regulator at the apical membrane of airway epithelial cellsProceedings of the National Academy of Sciences of the United States of America, 98
P. Baraldi, B. Cacciari, R. Romagnoli, K. Klotz, G. Spalluto, K. Varani, S. Gessi, S. Merighi, P. Borea (2001)
Pyrazolo[4,3‐e]1,2,4‐triazolo[1,5‐c]pyrimidine derivatives as adenosine receptor ligands: A starting point for searching A2B adenosine receptor antagonistsDrug Development Research, 53
Ji-long Jiang, A. Rhee, Louis Chang, Abraham Patchornik, X. Ji, Patricia Evans, N. Melman, Kenneth Jacobson (1997)
Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, 40 16
Luo Yan, J. Burbiel, A. Maaß, C. Müller (2003)
Adenosine receptor agonists: from basic medicinal chemistry to clinical developmentExpert Opinion on Emerging Drugs, 8
X. Ji, D. Lubitz, M. Olah, G. Stiles, K. Jacobson (1994)
Species differences in ligand affinity at central A3‐adenosine receptorsDrug Development Research, 33
J. Downey, M. Cohen, K. Ytrehus, Yongge Liu (1994)
Cellular Mechanisms in Ischemic Preconditioning: The Role of Adenosine and Protein Kinase C aAnnals of the New York Academy of Sciences, 723
M. Giudice, A. Borioni, C. Mustazza, F. Gatta, S. Dionisotti, C. Zocchi, E. Ongini (1996)
(E)-1-(Heterocyclyl or cyclohexyl)-2-[1,3,7-trisubstituted (xanthin-8-yl)] ethenes as A2a adenosine receptor antagonistsEuropean Journal of Medicinal Chemistry, 31
J. Bockaert, Jean Pin (1999)
Molecular tinkering of G protein‐coupled receptors: an evolutionary successThe EMBO Journal, 18
S. Kuroda, F. Takamura, Y. Tenda, H. Itani, Y. Tomishima, A. Akahane, K. Sakane (2001)
Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability.Chemical & pharmaceutical bulletin, 49 8
Sonja Hess, C. Müller, W. Frobenius, Ulrike Reith, K. Klotz, K. Eger (2000)
7-Deazaadenines bearing polar substituents: structure-activity relationships of new A(1) and A(3) adenosine receptor antagonists.Journal of medicinal chemistry, 43 24
S. Kuroda, A. Akahane, H. Itani, S. Nishimura, K. Durkin, T. Kinoshita, Y. Tenda, K. Sakane (1999)
Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist.Bioorganic & medicinal chemistry letters, 9 14
J. Francis, W. Cash, S. Psychoyos, G. Ghai, P. Wenk, R. Friedmann, C. Atkins, M Warren, P. Furness, J. Hyun (1988)
Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists.Journal of medicinal chemistry, 31 5
Jeongho Kim, J. Wess, A. Rhee, T. Schöneberg, K. Jacobson (1995)
Site-directed Mutagenesis Identifies Residues Involved in Ligand Recognition in the Human A2a Adenosine Receptor (*)The Journal of Biological Chemistry, 270
S. Kuroda, F. Takamura, Y. Tenda, H. Itani, Y. Tomishima, A. Akahane, Kazuo
Design , Synthesis and Biological Evaluation of a Novel Series of Potent , Orally Active Adenosine A 1 Receptor Antagonists with High Blood – Brain Barrier Permeability
J. Zablocki, Rao Kalla, Thao Perry, V. Palle, V. Varkhedkar, Dengming Xiao, A. Piscopio, T. Maa, A. Gimbel, Jia Hao, N. Chu, K. Leung, D. Zeng (2005)
The discovery of a selective, high affinity A(2B) adenosine receptor antagonist for the potential treatment of asthma.Bioorganic & medicinal chemistry letters, 15 3
S. Briddon, Richard Middleton, Y. Cordeaux, F. Flavin, Julia Weinstein, Michael George, B. Kellam, Stephen Hill (2004)
Quantitative analysis of the formation and diffusion of A1-adenosine receptor-antagonist complexes in single living cells.Proceedings of the National Academy of Sciences of the United States of America, 101 13
T. Fong, C. Strader (1994)
Functional mapping of the ligand binding sites of G‐Protein coupled receptorsMedicinal Research Reviews, 14
S. Kuroda, A. Akahane, H. Itani, S. Nishimura, K. Durkin, Y. Tenda, K. Sakane (2000)
Novel adenosine A1 receptor antagonists. Synthesis and structure-activity relationships of a novel series of 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5 -a]pyridines.Bioorganic & medicinal chemistry, 8 1
C. Müller, M. Diekmann, Mark Thorand, V. Ozola (2002)
[(3)H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors.Bioorganic & medicinal chemistry letters, 12 3
V. Colotta, D. Catarzi, F. Varano, F. Calabri, Ombretta Lenzi, G. Filacchioni, C. Martini, L. Trincavelli, F. Deflorian, S. Moro (2004)
1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.Journal of medicinal chemistry, 47 14
C. Müller, U. Schobert, J. Hipp, U. Geis, W. Frobenius, M. Pawłowski (1997)
Configurationally stable analogs of styrylxanthines as A2A adenosine receptor antagonistEuropean Journal of Medicinal Chemistry, 32
K. Jacobson, A. IJzerman, J. Linden (1999)
1,3‐dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptorsDrug Development Research, 47
K. Jacobson, D. Shi, C. Gallo-Rodriguez, M. Manning, C. Müller, J. Daly, J. Neumeyer, L. Kiriasis, W. Pfleiderer (1993)
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.Journal of medicinal chemistry, 36 18
Kenneth Jacobson, Carola Gallo-Rodriguez, N. Melman, Bilha Fischer, Michel Maillard, A. Bergen, P. Galen, Y. Karton (1993)
Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists.Journal of medicinal chemistry, 36 10
H. Nonaka, Michio Ichimura, M. Takeda, Yoshiko Nonaka, Jyunichi Shimada, Fumio Suzuki, Kazuo Yamaguchi, Hiroshi Kase (1994)
KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist.European journal of pharmacology, 267 3
S. Ceccarelli, A. D'alessandro, Michela Prinzivalli, S. Zanarella (1998)
Imidazo[1,2-a]quinoxalin-4-amines: A novel class of nonxanthine A1-adenosine receptor antagonistsEuropean Journal of Medicinal Chemistry, 33
E. Tilburg, P. Klein, M. Groote, M. Beukers, A. IJzerman (2001)
Substituted 4‐Phenyl‐2‐(phenylcarboxamido)‐1,3‐thiazole Derivatives as Antagonists for the Adenosine A1 ReceptorChemInform, 32
T. Maemoto, Miho Tada, Takuma Mihara, N. Ueyama, H. Matsuoka, K. Harada, T. Yamaji, K. Shirakawa, S. Kuroda, A. Akahane, A. Iwashita, N. Matsuoka, S. Mutoh (2004)
Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors.Journal of pharmacological sciences, 96 1
M. Chebib, Declan McKeveney, R. Quinn (2000)
1-Phenylpyrazolo[3,4-d]pyrimidines; structure-ac:tivity relationships for C6 substituents at A1 and A2A adenosine receptors.Bioorganic & medicinal chemistry, 8 11
M. Williams, J. Francis, G. Ghai, A. Braunwalder, S. Psychoyos, G. Stone, W. Cash (1987)
Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist.The Journal of pharmacology and experimental therapeutics, 241 2
L. Landells, M. Jensen, L. Orr, D. Spina, B. O'connor, C. Page (2000)
The role of adenosine receptors in the action of theophylline on human peripheral blood mononuclear cells from healthy and asthmatic subjectsBritish Journal of Pharmacology, 129
P. Baraldi, M. Tabrizi, D. Preti, A. Bovero, F. Fruttarolo, R. Romagnoli, A. Moorman, S. Gessi, S. Merighi, K. Varani, P. Borea (2004)
[3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors.Bioorganic & medicinal chemistry letters, 14 13
C. Vu, B. Peng, G. Kumaravel, G. Smits, Xiaowei Jin, D. Phadke, T. Engber, Carol Huang, Jennifer Reilly, S. Tam, Donna Grant, G. Hetu, Liqing Chen, Jianbo Zhang, R. Petter (2004)
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.Journal of medicinal chemistry, 47 17
Lisa Chang, Ronald Spanjersberg, J. Künzel, T. Mulder-Krieger, Gijs Hout, M. Beukers, J. Brussee, A. IJzerman (2004)
2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists.Journal of medicinal chemistry, 47 26
E. Priego, Jacobien Kuenzel, A. IJzerman, M. Camarasa, M. Pérez-Pérez (2002)
Pyrido[2,1-f]purine-2,4-dione derivatives as a novel class of highly potent human A(3) adenosine receptor antagonists.Journal of medicinal chemistry, 45 16
X. Ji, K. Jacobson (1999)
Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors.Drug design and discovery, 16 3
S. Moro, F. Deflorian, G. Spalluto, G. Pastorin, B. Cacciari, Soo-Kyung Kim, K. Jacobson (2003)
Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling.Chemical communications, 24
A. Hayallah, J. Sandoval-Ramírez, Ulrike Reith, U. Schobert, Birgit Preiss, B. Schumacher, J. Daly, C. Müller (2002)
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.Journal of medicinal chemistry, 45 7
E. Camaioni, S. Costanzi, S. Vittori, R. Volpini, K. Klotz, G. Cristalli (1998)
New substituted 9-alkylpurines as adenosine receptor ligands.Bioorganic & medicinal chemistry, 6 5
Q. Jiang, A. Rhee, Jeongho Kim, Susan Yehle, Jürgen Wess, Kenneth Jacobson (1996)
Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition.Molecular pharmacology, 50 3
P. Baraldi, B. Cacciari, R. Romagnoli, G. Spalluto, A. Monopoli, E. Ongini, K. Varani, P. Borea (2002)
7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility.Journal of medicinal chemistry, 45 1
Peter Richardson, Hiroshi Kase, P. Jenner (1997)
Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease.Trends in pharmacological sciences, 18 9
Yong‐Chul Kim, M. Zwart, Louis Chang, S. Moro, J. Künzel, N. Melman, A. IJzerman, K. Jacobson (1998)
Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.Journal of medicinal chemistry, 41 15
M. Olah, Kenneth Jacobson, Kenneth Jacobson, Gary Stiles (1990)
Purification and characterization of bovine cerebral cortex A1 adenosine receptor.Archives of biochemistry and biophysics, 283 2
J. Fozard, C. Mccarthy (2002)
Adenosine receptor ligands as potential therapeutics in asthma.Current opinion in investigational drugs, 3 1
D. Dassesse, A. Massie, R. Ferrari, C. Ledent, M. Parmentier, L. Arckens, M. Zoli, S. Schiffmann (2001)
Functional striatal hypodopaminergic activity in mice lacking adenosine A2A receptorsJournal of Neurochemistry, 78
W. Barrington, K. Jacobson, G. Stiles (1990)
Glycoprotein nature of the A2-adenosine receptor binding subunit.Molecular pharmacology, 38 2
D. Lubitz (2001)
Adenosine in the treatment of stroke: yes, maybe, or absolutely not?Expert Opinion on Investigational Drugs, 10
Ever since the discovery of the hypotensive and bradycardiac effects of adenosine, adenosine receptors continue to represent promising drug targets. First, this is due to the fact that the receptors are expressed in a large variety of tissues. In particular, the actions of adenosine (or methylxanthine antagonists) in the central nervous system, in the circulation, on immune cells, and on other tissues can be beneficial in certain disorders. Second, there exists a large number of ligands, which have been generated by introducing several modifications in the structure of the lead compounds (adenosine and methylxanthine), some of them highly specific. Four adenosine receptor subtypes (A1, A2A, A2B, and A3) have been cloned and pharmacologically characterized, all of which are G protein‐coupled receptors. Adenosine receptors can be distinguished according to their preferred mechanism of signal transduction: A1 and A3 receptors interact with pertussis toxin‐sensitive G proteins of the Gi and Go family; the canonical signaling mechanism of the A2A and of the A2B receptors is stimulation of adenylyl cyclase via Gs proteins. In addition to the coupling to adenylyl cyclase, all four subtypes may positively couple to phospholipase C via different G protein subunits. The development of new ligands, in particular, potent and selective antagonists, for all subtypes of adenosine receptors has so far been directed by traditional medicinal chemistry. The availability of genetic information promises to facilitate understanding of the drug–receptor interaction leading to the rational design of a potentially therapeutically important class of drugs. Moreover, molecular modeling may further rationalize observed interactions between the receptors and their ligands. In this review, we will summarize the most relevant progress in developing new therapeutic adenosine receptor antagonists. © 2005 Wiley Periodicals, Inc.
Medicinal Research Reviews – Wiley
Published: Mar 1, 2006
Keywords: G protein‐coupled receptor; adenosine receptor; antagonists
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.